Share on StockTwits

Brean Capital increased their target price on shares of Medivation (NASDAQ:MDVN) from $100.00 to $105.00 in a research note issued on Friday. The firm currently has a “buy” rating on the stock. Brean Capital’s target price would suggest a potential upside of 39.50% from the company’s current price.

MDVN has been the subject of a number of other recent research reports. Analysts at Credit Suisse raised their price target on shares of Medivation from $95.00 to $98.00 in a research note on Monday. They now have an “outperform” rating on the stock. Separately, analysts at Aegis reiterated a “buy” rating on shares of Medivation in a research note on Wednesday, July 2nd. Finally, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Medivation in a research note on Monday, June 23rd. They now have a $81.00 price target on the stock, down previously from $83.00. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $94.00.

Medivation (NASDAQ:MDVN) traded up 8.49% on Friday, hitting $81.66. The stock had a trading volume of 3,105,229 shares. Medivation has a 52 week low of $48.15 and a 52 week high of $88.20. The stock’s 50-day moving average is $75.76 and its 200-day moving average is $71.52. The company’s market cap is $6.249 billion.

Medivation (NASDAQ:MDVN) last announced its earnings results on Thursday, August 7th. The company reported $0.60 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.24 by $0.36. The company had revenue of $148.09 million for the quarter, compared to the consensus estimate of $126.46 million. During the same quarter last year, the company posted ($0.07) earnings per share. Medivation’s revenue was up 111.1% compared to the same quarter last year. Analysts expect that Medivation will post $1.50 EPS for the current fiscal year.

Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.

Receive News & Ratings for Medivation Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivation Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.